We’ve recently updated our valuation analysis.

Geron Valuation

Is GERN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GERN?

Other financial metrics that can be useful for relative valuation.

GERN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue535.4x
Enterprise Value/EBITDA-6.4x
PEG Ration/a

Price to Book Ratio vs Peers

How does GERN's PB Ratio compare to its peers?

GERN PB Ratio vs Peers
The above table shows the PB ratio for GERN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average2.2x
CRNX Crinetics Pharmaceuticals
MORF Morphic Holding
VCYT Veracyte
GERN Geron

Price-To-Book vs Peers: GERN is expensive based on its Price-To-Book Ratio (6.2x) compared to the peer average (2.2x).

Price to Earnings Ratio vs Industry

How does GERN's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: GERN is expensive based on its Price-To-Book Ratio (6.2x) compared to the US Biotechs industry average (1.6x)

Price to Book Ratio vs Fair Ratio

What is GERN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GERN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio6.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate GERN's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of GERN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GERN ($2.34) is trading below our estimate of fair value ($5.8)

Significantly Below Fair Value: GERN is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies